Le sfide dell’impresa biotech (The challenges of the biotech company)


  • Roberto Vona




economy and management of biotechnologies supply chain, technology ventures, entrepreneurship in the sciences, spin-off management


Purpose of the paper: This paper deals with the complexity of the entrepreneurial challenge of biotechnologies by adopting a business interpretation approach. It aims to explore its “industrial” characteristics in a supply chain perspective and to analyse its strategic evolutionary dynamics. In particular, the paper will focus on “sectoral” specifities that favour development paths which are more directed towards vertical integration solutions, i.e. sharing projects and partnerships. It provides policy propositions that are aimed at promoting the translation of the potential to make scientific discoveries into business activities.
Methodology: A conceptual analysis of the elements that characterize the foundational and “structural” dynamics of the biotechnologies supply chain has been adopted.
Findings: The analysis enabled the exploration of technological, economic and business peculiarities, as well as the evolutionary trajectories of the biotechnologies supply chain while focusing on the policies connected to the development of new business initiatives containing a high degree of technological innovation.
Research limits: The paper is the result of reflections founded on analyses and conceptualizations of recent literature about management of “science based” businesses. Such considerations could be integrated and “verified” with the help of more exhaustive and updated empirical analyses.
Practical implications: The present study could contribute to a better understanding of the “biotechnologies phenomenon” from the perspective of the management scholar and the business and public decision-maker.
Originality of the paper: This paper responds to the need for further cognitive inquiries into the biotechnologies sector from an economic and managerial standpoint.


ABELL D.F. (1980), Defining the business: the starting point of strategic planning, (Bergen County), Prentice Hall, Englewood Cliffs, New Jersey.

ABERNATHY W.J., CLARK K.B. (1985), “Innovation: mapping the winds of creative destruction”, Research Policy, vol. 14, n. 1, pp. 3-22.

ACEMOGLU D., GRIFFITH R., AGHION P., ZILIBOTTI F. (2010), “Vertical integration and technology: theory and evidence”, Journal of the European Economic Association, vol. 8, n. 5, pp. 989-1033.

AFUAH A. (2001), “Dynamic boundaries of the firm: are firms better off being vertically integrated in the face of a technological change?”, Academy of Management journal, vol. 44, n. 6, pp. 1211-1228.

AGHION P., TIROLE J. (1994), “On the management of innovation”, Quarterly Journal of Economics, vol. 109, n. 4, pp. 1185-1207.

AHUJA G. (2000), “The duality of collaboration: inducements and opportunities in the formation of interfirm linkages”, Strategic Management Journal, vol. 21, n. 3, pp. 317-343.

ARORA A., GAMBARDELLA A. (1990), “Complementarity and external linkages: the strategies of the large firms in biotechnology”, Journal of Industrial Economics, n. 4, pp. 361-379.

AZZONE G., DALLA POZZA I. (2003), “An integrated strategy for launching a new product in the biotech industry”, Management Decision, vol. 41, n. 9, pp. 832-843.

BACCARANI C. (1995), “I processi di sviluppo dell’impresa minore”, Sinergie, n. 38, pp. 57-62.

BACCARANI C. (2005), Imprese commerciali e sistema distributivo, Giappichelli Ed., Torino.

BACCARANI C., GOLINELLI G.M. (2003), “L’impresa inesistente: relazionali tra immagine e strategia”, Sinergie, n. 61/62, pp. 213-225.

BACHMANN R. (2003), Industrial Biotech - New Value-Creation Opportunities, Presentation at the Bio-Conference, New York, 5-6 giugno.

BAKER A. (2003), “Biotechnology’s growth - innovation paradox and the new model for success”, Journal of Commercial Biotechnology, vol. 9, n. 4, pp. 286-288.

BARLEY S.R., FREEMAN J., HYBELS R.C. (1992), “Strategic alliances in commercial biotechnology”, in Nohria N., Eccles R.(a cura di), Networks and Organizations: Structure, Form and Action, HBS Press, Boston, MA., pp. 311-347.

BARNEY J.B. (1991), “Firm resources and sustained competitive advantage”, Journal of Management, vol. 17, n. 1, pp. 99-120.

BELLINI N., FERRUCCI L. (a cura di) (2002), Ricerca universitaria e processi di innovazione, Franco Angeli, Milano.

BETTIS R.A., HITT M.A. (1995), “The new competitive landscape”, Strategic Management Journal, vol. 16, n. S1, pp. 7-19.

BURNS T., STALKER G.M. (1961), The management of innovation, Tavistock Pubblications, London.

BYERS T., DORF R., NELSON A., VONA R. (2011), Technology Ventures. Management dell’imprenditorialità e dell’innovazione, McGraw-Hill, Milano.

COHENDET P., KERN F., MEHMANPAZIR B., MUNIER F. (1999), “Knowledge coordination, competence creation and integrated networks in globalised firms”, Cambridge Journal of Economics, vol. 23, n. 2, pp. 225-241.

COLEMAN J. S. (1988), “Social capital in the creation of human capital” American journal of sociology, n. 94, pp. 95-120.

COOKE P. (2002), “Biotechnology clusters as regional, sectoral innovation systems”, International Regional Science Review, vol. 25, n. 1, pp. 8-37.

DA SILVA E.J. (2004), “The colours of biotechnology: science, development and humankind”, Electronic Journal of Biotechnology, n. 7, editorial (www.ejbiotechnology.info/content/vol7/issue3/editorial.html).

DEEDS D.L., HILL C.W.L. (1996), “Strategic alliances and the rate of new product development: an empirical study of entrepreneurial biotechnology firms”, Journal of Business Venturing, vol. 11, n. 1, pp. 41-55.

DI BERNARDO B., RULLANI E., VACCÀ S. (1986), “Cambiamento tecnologico ed economia d’impresa”, Economia e Politica Industriale, n. 50, pp. 79-122.

DI GREGORIO D., SHANE S. (2003), “Why do some universities generate more start-ups than others?”, Research Policy, vol. 32, n. 2, pp. 209-227.

DURANT J., BAUER M.W., GASKELL G. (a cura di) (1998), Biotechnology in the public sphere: a European sourcebook, NMSI Trading Ltd, Londra.

EISENHARDT K.M., SCHOONHOVEN C.B. (1996), “Resource-based view of strategic alliance formation: Strategic and social effects in entrepreneurial firms”, Organization Science, vol. 7, n. 2, pp. 136-150.

FRANCH M., PANATI G. (1987), Marketing e Impresa, Cedam, Padova.

FISHER L.M. (1997), “The rocky road from start up to big time player: Biogen triumph against the odds”, Strategy&Business, n. 3, pp. 55-63.

GASKELL G., EINSIEDEL E., PRIEST S., TEN EYCK T., ALLUM N., TORGERSEN H. (2001), “Troubled waters-The Atlantic divide on biotechnology policy” in Gaskell G. Bauer M.W. (a cura di), Biotechnology 1996-2000: The Years of Controversy, Science Museum, Londra, pp. 96-115.

GEORGE G., ZAHRA S.A., WOOD D.R. Jr. (2002), “The effects of business-university alliances on innovative output and financial performance: a study of publicly traded biotechnology companies”, Journal of Business Venturing, vol. 17, n. 6, pp. 577-609.

GIOVANNETTI G.T., MORRISON S.W. (2000), Convergence. The biotechnology industry report, Ernst & Young, Palo Alto.

GRANDO A., VERONA G., VICARI S. (2006), Tecnologia, Innovazione, Operations, Egea, Milano.

GRANOVETTER M. (1985), “Economic action and social structure: the problem of embeddedness”, American journal of sociology, n. 91, pp. 481-510.

GRANT R.M., BADENFULLER C. (2004), “A knowledge accessing theory of strategic alliances”, Journal of Management Studies, vol. 41, n. 1, pp. 61-84.

GREIS N.P., DIBNER M.D., BEAN A.S. (1995), “External partnering as a response to innovation barriers and global competition in biotechnology”, Research Policy, vol. 24, n. 4, pp. 609-630.

GURAU C. (2004), “Positioning strategies in the value-added chain of the biopharmaceutical sector: the case of UK SMEs”, Journal of Consumer Marketing, vol. 21, n. 7, pp. 476-485.

HAAR B. (2001), “Venture capital funding for biotech pharmaceutical companies in an integrated financial services market: regulatory diversity within the EC”, European Business Organization Law Review, vol. 2, n. 3/4, pp. 585-602.

HARRIGAN K.R. (1984), “Formulating vertical integration strategies”, Academy of management review, vol. 9, n. 4, pp. 638-652.

HENDERSON R.M., COCKBURN I. (1996), “Scale, scope, and spillovers: the determinants of research productivity in drug discovery”, RAND Journal of Economics, n. 27, pp. 32-59.

HILL C.W.L. (1992), “Strategies for exploiting technological innovations: when and when not to license”, Organization Science, vol. 3, n. 3, pp. 428-441.

HILL C.W.L., ROTHAERMEL F.T. (2003), “The performance of incumbent firms in the face of radical technological innovation”, Academy of Management Review, vol. 28, n. 2, pp. 257-274.

KLEIN B., CRAWFORD R., ALCHIAN A. (1978), “Vertical integration, appropriable rents and the competitive contracting process”, Journal of Law and Economics, vol. 21, n. 2, pp. 297-326.

KOGUT B., SHAN W., WALKER G. (1992), “The make-or-cooperate decision in the context of an industry network”, in Nohria N., Eccles R.(a cura di ), Networks and Organizations: Structure, Form and Action, HBS Press, pp. 348-365, Boston, MA.

KOZA M.P., LEWIN A.Y. (1998), “The co-evolution of strategic alliances”, Organization Science, vol. 9, n. 3, pp. 255-264.

LAYCOCK M. (2005), “Collaborating to compete: achieving effective knowledge sharing in organizations”, The Learning Organization, vol. 12, n. 6, pp. 523-539.

LERNER J., MERGES R.P. (1998), “The control of technology alliances: an empirical analysis of the biotechnology industry”, Journal of Industrial Economics, vol. 46, n. 2, pp. 125-156.

LERNER J., SHANE H., TSAI A. (2003), “Do equity financing cycles matter? Evidence from biotechnology alliances”, Journal of Financial Economics, vol. 67, n. 3, pp. 411-446.

LUUKKONEN T. (2005), “Variability in organisational forms of biotechnology firms.” Research Policy, vol. 34, n. 4, pp. 555-570.

MADHOK A., OSEGOWITSCH T. (2000), “The international biotechnology industry: a dynamic capabilities perspective”, Journal of International Business Studies, vol. 31, n. 2, pp. 325-335.

MCMURRAY A., JONES R. (2003), “A new model to evaluate the market for biotechnology”, Journal of Commercial Biotechnology, vol. 10, n. 1, pp. 78-84.

MONTEVERDE K., TEECE D.J. (1982), “Vertical integration and supplier switching costs”, The Bell Journal of Economics, vol. 13, n. 1, pp. 206-213.

MUFFATTO M., GIARDINA G.A.M. (2003), “Innovazioni nei processi di ricerca in campo farmaceutico”, Economia & Management, vol. 6, pp. 108-120.

NELSON R.R. (2004), “The market economy, and the scientific commons”, Research policy, vol. 33, n. 3, pp. 455-471.

OLIVER A.L. (2001), “Strategic alliances and the learning life-cycle of biotechnology firms”, Organization Studies, vol. 22, n. 3, pp. 467-489.

PAMMOLLI F. (1996), Innovazione, concorrenza e strategie di sviluppo nell’industria farmaceutica, Guerini, Milano.

PANATI G. (2003), “Interrogativi in tema di teologia dell’imprenditorialità”, Sinergie, n. 61/62, pp. 13-33.

PANATI G. (1989), “Impresa e ambiente: griglia delle regole e matrice delle convenienze d’impresa”, Sinergie, n. 18, pp. 39.

PANATI G., GOLINELLI G.M. (1992), Tecnica economica industriale e commerciale, Nuova Italia Scientifica, Roma.

PENROSE E. (1959), The theory of the growth of the firm, Basil Blackwell, Oxford.

PICCALUGA A., BALDERI C. (2006), La valorizzazione della ricerca nelle Università italiane. Quarto rapporto annuale (dati relativi al periodo 2002-2005), Network per la Valorizzazione della Ricerca Universitaria.

PISANO G.P. (1990), “The R&D boundaries of the firm: an empirical analysis”, Administrative Science Quarterly, vol. 35, n. 1, pp. 153-176.

PISANO G.P. (1991), “The governance of innovation: vertical integration and collaborative agreements in the biotechnology industry”, Research Policy, vol. 20, n. 3, pp. 237-249.

PISANO G.P. (1997), “R&D performance, collaborative arrangements, and the market-for-know-how: a test of the ‘lemons’ hypothesis in biotechnology”, Working Paper, Harvard Business School.

POWELL W.W. (1998), “Learning from collaboration: knowledge and networks in the biotechnology and pharmaceutical industries”, California Management Review, vol. 40, n. 3, pp. 228-241.

POWELL W.W. (1996), “Inter-organizational collaboration in the biotechnology industry”, Journal of Institutional and Theoretical Economics (JITE)/Zeitschrift für die gesamte Staatswissenschaft, n. 152, pp. 197-215.

POWELL W.W., KOPUT K.W., SMITH-DOERR L. (1996), “Interorganizational collaboration and the locus of innovation: Networks of learning in biotechnology”, Administrative science quarterly, n. 41, pp. 116-145.

QUINN J.B. (1992), “The intelligent enterprise a new paradigm”, The Executive, vol. 6, n. 4, pp. 48-63.

ROTHAERMEL F.T. (2000), “Technological discontinuities and the nature of competition”, Technology Analytical Strategic Management, vol. 12, n. 2, pp. 149-160.

ROTHAERMEL F.T., DEEDS D.L. (2004), “Exploration and exploitation alliances in biotechnology: a system of new product development”, Strategic Management Journal, vol. 25, n. 3, pp. 201-221

ROTHAERMEL F.T. (2001), “Incumbent’s advantage through exploiting complementary assets via interfirm cooperation”, Strategic Management Journal, vol. 22, n. 6/7, pp. 687-699.

ROTHAERMEL F.T., HITT M.A., JOBE L.A. (2006), “Balancing vertical integration and strategic outsourcing: effects on product portfolio, product success, and firm performance”, Strategic management journal, vol. 27, n. 11, pp. 1033-1056.

SCHUMPETER J.A. (1942), Capitalism, Socialism and Democracy, Harper & Row, New York.

SHAN W., WALKER G., KOGUT B. (1994), “Interfirm cooperation and startup innovation in the biotechnology industry”, Strategic management journal, vol. 15, n. 5, pp. 387-394.

STUART T.E., DING W.W. (2006), “When do scientists become entrepreneurs? The social structural antecedents of commercial activity in the academic life sciences”, American Journal of Sociology, vol. 112, n. 1, pp. 97-144.

STUART T.E., OZDEMIR S.Z., DING W.W. (2007), “Vertical alliance networks: The case of university-biotechnology-pharmaceutical alliance chains”, Research Policy, vol. 36, n. 4, pp. 477-498

TEECE D.J. (1986), “Profiting from technological innovation: implications for integration, collaboration, licensing and public policy”, Research Policy, vol. 15, n. 6, pp. 285-305.

TEECE D.J. (1992), “Competition, cooperation, and innovation: organizational arrangements for regimes of rapid technological progress”, Journal of Economic Behavior and Organization, vol. 18, n. 1, pp. 1-25.

TEECE D.J., PISANO G.P., SHUEN A. (1997), “Dynamic capabilities and strategic management”, Strategic Management Journal, vol. 18, n. 7, pp. 509-533.

TYBJEE T., HARDIN J. (2004), “Biotech-pharma alliances: strategies, structures and financing”, Journal of Commercial Biotechnology, vol. 10, n. 4, pp. 329-339.

VALLE F., GAMBARDELLA A. (1993). “Biological’revolution and strategies for innovation in pharmaceutical companies”, R&D Management, vol. 23, n. 4, pp. 287-302.

VONA R., DI PAOLA N., “Mercato e nuova imprenditorialità nelle Biotecnologie”, in Donadio S., Marino G., (a cura di) Biotecnologie Microbiche, Casa Editrice Ambrosiana, Milano.
VONA R. (2007), Management delle biotecnologie. Competizione, innovazione e sviluppo imprenditoriale, F. Angeli, Milano.

WALSH V., NIOSI J., MUSTAR P. (1995), “Small-firm formation in biotechnology: a comparison of France, Britain and Canada”, Technovation, vol. 15, n. 5, pp. 303-327.

WILLIAMSON O.E. (1981), “The economics of organization: The transaction cost approach”, American journal of sociology, n. 87, pp. 548-577.

ZUCKER L.G., DARBY M.R. (1996), “Star scientists and institutional transformation: patterns of invention and innovation in the formation of the biotechnology industry”, Proceedings of the National Academy of Science, vol. 93, n. 23, pp. 12709-12716.

ZUCKER L.G., DARBY M.R., ARMSTRONG J.S. (1998a), “Geographically localized knowledge: spillovers or markets?”, Economic Inquiry, vol. 36, n. 1, pp. 65-86.

ZUCKER L.G., DARBY M.R., ARMSTRONG J.S. (2002), “Commercializing knowledge: university science, knowledge capture, and firm performance in biotechnology”, Management Science, vol. 48, n. 1, pp. 138-153.

ZUCKER L.G., DARBY M.R., BREWER M.B. (1998b), “Intellectual human capital and the birth of the U.S. biotechnology enterprises”, American Economic Review, vol. 88, n. 1, pp. 290-306.